M.D., Chief Medical Officer, Transplant Genomics, Inc.
Roy First, M.D. is Chief Medical Officer at Transplant Genomics, Inc. Previously he was VP and Global Therapeutic Leader (Transplantation) at Astellas Pharma, and Medical Director of Kidney Transplantation at the University of Cincinnati. He has published more than 390 articles on transplantation, as well as 39 book chapters and two books. He is a past President of the American Society of Transplantation (AST). In 2013 he received the AST Lifetime Achievement Award.
Clinical Use of Genomic Biomarkers in Transplantation
Graft loss is significant and progressive after kidney transplantation. Renal function (serum creatinine) is a lagging indicator of graft injury. An abnormal surveillance biopsy results in poor long-term outcomes.
Implementing the use of diagnostic and predictive biomarkers into clinical practice offers the opportunity to improve long-term outcomes.